Hydroxyurea Use Among Medicaid Beneficiaries with Sickle Cell Disease in California and Georgia, 2006–2016

Details

• Corporate Authors:
  National Center on Birth Defects and Developmental Disabilities (Centers for Disease Control and Prevention). Sickle Cell Data Collection Program.
• Description:
  During 2006–2016, the use of hydroxyurea (HU) among Medicaid beneficiaries with sickle cell disease (SCD) who lived in California or Georgia increased. However, many beneficiaries with severe complications of SCD do not use HU.
  
  HU was approved by the FDA in 1998 for the treatment of severe SCD in adults and in 2017 for the treatment of pediatric patients. It can decrease several complications of SCD, including severe acute pain episodes and acute chest syndrome, and may lead to fewer hospitalizations and improved survival.
  
  CS 311531-A June 04, 2021
  
  SCDC-data-brief-HU-h.pdf
  
  
• Subjects:
  Anemia, Sickle Cell/therapy Antisickling Agents/therapeutic Use Hydroxyurea/therapeutic Use
• Series:
  Sickle Cell Data Collection (SCDC)
• Document Type:
  Text
• Genre:
  Fact Sheet
• Place as Subject:
  California ; Georgia
• Pages in Document:
  2 unnumbered pages
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha-512:8c07f4817ceda5cc0814cc5740c26992777fabcd8acb1e6b97259054b9f0b5cd183a1c87a06b585936ab59a6c220e2528917ee266ba9c3f7c79cd1e67c7e6a31
• Download URL:
  https://stacks.cdc.gov/view/cdc/133048/cdc_133048_DS1.pdf
• File Type:
  [PDF - 434.43 KB ]